Sign inCreate account

Report workspace tools

NCT05565248TERMINATEDanonymous

An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)

Sponsor

Source record

CRISPR Therapeutics AG

Phase

Source record

Phase 1

Modality

AI-normalized

gene therapy

Target

AI-normalized

Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.

Indication / condition

AI-normalized

Diabetes Mellitus

Intervention

Source record

VCTX211

Source & freshness

Source record

NCT ID

NCT05565248

Original source

ClinicalTrials.gov

Source last updated

May 07, 2026

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05565248

Title

An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)

Sponsor

CRISPR Therapeutics AG

Status

TERMINATED

Phase

Phase 1

Condition raw

Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases

Condition normalized

Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.

Target normalized

Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.

Interventions

VCTX211

Public preview

Source record

CRISPR Therapeutics AG is advancing VCTX211, a combination product aimed at treating Type 1 Diabetes Mellitus (T1D) through innovative gene editing technology. The asset is positioned in a competitive landscape with a growing focus on cell therapies and gene editing for autoimmune diseases. The termination of the trial indicates a strategic pivot to follow-up studies (VCTX-201), which may enhance patient outcomes and data robustness. The T1D market is substantial, with increasing demand for novel therapies that offer improved glycemic control and reduced reliance on exogenous insulin. The collaboration with ViaCyte adds credibility and expertise in cell therapy, potentially strengthening market positioning.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05565248

Status

TERMINATED

Phase

Phase 1

Sponsor

CRISPR Therapeutics AG

Executive brief

Investment-Ready Snapshot

CRISPR Therapeutics AG is advancing VCTX211, a combination product aimed at treating Type 1 Diabetes Mellitus (T1D) through innovative gene editing technology. The asset is positioned in a competitive landscape with a growing focus on cell therapies and gene editing for autoimmune diseases. The termination of the trial indicates a strategic pivot to follow-up studies (VCTX-201), which may enhance patient outcomes and data robustness. The T1D market is substantial, with increasing demand for novel therapies that offer improved glycemic control and reduced reliance on exogenous insulin. The collaboration with ViaCyte adds credibility and expertise in cell therapy, potentially strengthening market positioning.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 07, 2026
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05565248

Indication

Diabetes Mellitus

Modality

gene therapy

Target

Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.

Intervention

VCTX211

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.